- Investing Ideas
- /
- Australian Biotech Stocks
Australian Biotech Stocks
Results
45
Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.
45 companies
CSL
Market Cap: AU$83.1b
Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
CSL
AU$172.46
7D
-0.6%
1Y
-39.3%
Telix Pharmaceuticals
Market Cap: AU$3.8b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
TLX
AU$11.25
7D
-4.4%
1Y
-54.5%
Mesoblast
Market Cap: AU$3.5b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$2.76
7D
-1.8%
1Y
-9.5%
Neuren Pharmaceuticals
Market Cap: AU$2.4b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$19.02
7D
-0.6%
1Y
58.4%
PYC Therapeutics
Market Cap: AU$982.8m
A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
PYC
AU$1.69
7D
-1.5%
1Y
27.7%
Immutep
Market Cap: AU$626.3m
A biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.
IMM
AU$0.42
7D
-4.5%
1Y
21.4%
Clinuvel Pharmaceuticals
Market Cap: AU$624.0m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$12.43
7D
-3.3%
1Y
5.6%
Dimerix
Market Cap: AU$333.2m
A biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia.
DXB
AU$0.56
7D
0%
1Y
56.3%
Orthocell
Market Cap: AU$297.1m
A regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally.
OCC
AU$1.10
7D
2.3%
1Y
-17.7%
Botanix Pharmaceuticals
Market Cap: AU$265.7m
Operates as a commercial dermatology company in Australia and the United States.
BOT
AU$0.14
7D
12.5%
1Y
-70.3%
Mayne Pharma Group
Market Cap: AU$263.2m
A specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
MYX
AU$3.24
7D
2.5%
1Y
-29.1%
Aroa Biosurgery
Market Cap: AU$257.0m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.74
7D
4.9%
1Y
-0.7%
Tetratherix
Market Cap: AU$163.6m
Engages in biomaterial and regenerative medicine business in Australia and internationally.
TTX
AU$3.25
7D
-2.7%
1Y
n/a
Paradigm Biopharmaceuticals
Market Cap: AU$158.6m
Engages in the research and development of therapeutic products for human use in Australia.
PAR
AU$0.37
7D
12.1%
1Y
-7.5%
Vita Life Sciences
Market Cap: AU$142.0m
A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.
VLS
AU$2.60
7D
1.6%
1Y
32.7%
LTR Pharma
Market Cap: AU$118.1m
A clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia.
LTP
AU$0.65
7D
2.4%
1Y
-14.5%
Imugene
Market Cap: AU$113.5m
A clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.
IMU
AU$0.36
7D
10.8%
1Y
-75.9%
Trajan Group Holdings
Market Cap: AU$103.7m
Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.
TRJ
AU$0.68
7D
2.3%
1Y
-38.2%
Alterity Therapeutics
Market Cap: AU$97.9m
Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.
ATH
AU$0.009
7D
12.5%
1Y
-10.0%
Radiopharm Theranostics
Market Cap: AU$88.6m
A clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.
RAD
AU$0.025
7D
-3.8%
1Y
0%
Amplia Therapeutics
Market Cap: AU$87.2m
A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.
ATX
AU$0.17
7D
30.8%
1Y
100.0%
Medical Developments International
Market Cap: AU$62.0m
Manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally.
MVP
AU$0.55
7D
1.9%
1Y
27.9%
Genetic Signatures
Market Cap: AU$53.4m
Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.
GSS
AU$0.23
7D
-2.1%
1Y
-63.6%
Syntara
Market Cap: AU$50.6m
Operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia.
SNT
AU$0.031
7D
-6.1%
1Y
-60.8%
Vitura Health
Market Cap: AU$40.4m
Engages in the sale and distribution of medicinal cannabis products in Australia.
VIT
AU$0.061
7D
-1.6%
1Y
-30.7%
BCAL Diagnostics
Market Cap: AU$38.6m
A screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer.
BDX
AU$0.10
7D
5.0%
1Y
8.2%
Little Green Pharma
Market Cap: AU$38.2m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.13
7D
0%
1Y
4.2%
NeuroScientific Biopharmaceuticals
Market Cap: AU$34.9m
Engages in the research and development of biomedical products targeting neurodegenerative conditions.
NSB
AU$0.10
7D
5.0%
1Y
218.2%
Avecho Biotechnology
Market Cap: AU$33.1m
A biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India.
AVE
AU$0.009
7D
0%
1Y
200.0%
Noxopharm
Market Cap: AU$28.1m
A biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia.
NOX
AU$0.096
7D
-2.0%
1Y
2.1%
Tissue Repair
Market Cap: AU$23.6m
A clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia.
TRP
AU$0.39
7D
3.3%
1Y
44.4%
IDT Australia
Market Cap: AU$21.8m
Engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States.
IDT
AU$0.051
7D
0%
1Y
-49.0%
Peak Processing
Market Cap: AU$20.0m
Manufactures, distributes, and sells recreational cannabis products in Canada and the United States.
PKP
AU$0.02
7D
0%
1Y
n/a
Cann Group
Market Cap: AU$15.4m
Engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe.
CAN
AU$0.01
7D
11.1%
1Y
-73.7%
Chimeric Therapeutics
Market Cap: AU$12.3m
A clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia.
CHM
AU$0.003
7D
0%
1Y
-50.0%
Immuron
Market Cap: AU$11.4m
A biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.
IMC
AU$0.035
7D
-2.8%
1Y
-56.3%